Rapamycin plus Lucentis versus Lucentis alone for age-related macular degeneration: phase 2 RCT
This phase 2 randomized controlled trial assessed whether adding ocular sirolimus (rapamycin) to Lucentis improved outcomes compared to Lucentis plus placebo in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. The study evaluated safety and efficacy, though specific findings, sample size, and effect sizes are not reported in the available material.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Jan 10, 2013 · Discovered: Sep 19, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Patients with sub-foveal choroidal neovascularization secondary to age-related macular degeneration
- Primary outcome
- Safety and efficacy of ocular sirolimus formulation in combination with Lucentis
- Effect size
- —
- Significance
- Not reported
- Journal
- Santen Inc.
- Published
- Jan 10, 2013
Sources
Primary source
- Santen Inc. ↗Clinical trial
Source versions
Assessment history
9/24/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.